Towards research equity - Challenges of safety monitoring during clinical trials in resource-limited settings

West Indian Medical Journal

Volumn 56, Issue 2, 2007, Pages 163-165

  Van den Broeck, J ^a   Robinson, A K L ^b  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b Vector Borne Disease Sector Disease Control Programme   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNICABLE DISEASE; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; GENETIC DIFFERENCE; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; MORBIDITY; NUTRITIONAL STATUS; PATIENT MONITORING; PHARMACEUTICAL CARE; PRIMARY HEALTH CARE; RESEARCH ETHICS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STANDARDIZATION; WELLBEING;

EID: 34548215279     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0043-31442007000200011     Document Type: Article

References (17)

1. South African Medical Research Council. Guidelines for Good Practice in the Conduct of Clinical Trials in Human Participants in South Africa. Department of Health, Pretoria, 2000.
2. Freeman J. They test new drugs don't they? Drug safety: a shared responsibility. Edinburgh Churchill Livingstone, 1991: pp 13-23.
3. Wong ICK. Pharmacovigilance resources in the United Kingdom. The Pharm J 1999; 263: 285-8.
4. Musaka-Monico S. Unprecedented response required for strengthening Africa's HIV vaccine research. AAVP News letter, Issue 2, p 3.
5. Doumbo O. It takes a village: medical research and ethics in Mali. Science 2005; 307: 679-81.
6. Bhutta Z. Standards of care in research. BMJ 2004; 329: 1114-5.
7. World Health Organization Executive Board. EB115/30. Report on the Ministerial Summit on Health Research, Mexico City (16-20 November 2004), 2005.
8. Guay LA, Musoke P, Flemming T, Bagenda D, Allen M, Nakabiito C et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
9. Wood R. Nevirapine toxicity - implications for management of South African patients. S Afr Med J 2005; 95: 253-257.
10. European Agency for the Evaluation of Medicinal Products, ICH Topic E6. Step 5, Consolidated Guideline, 1996.
11. Bash PE. Textbook of International Health. New York, Oxford University Press, 1999; p 486.
12. Fogg L, Gross D. Threats to validity in randomized clinical trials. Res Nurs Health 200; 23: 79-87.
13. Lilford RJ. Ethics of clinical trials from a Bayesian and decision analytic perspective: whose equipoise is it anyway? BMJ 2003; 326: 980-1.
14. Kramer BS, Wilentz J, Burklow J, Friedman LM, Hodes R, Kirschstein R et al. Getting it right: being smarter about clinical trials. A major NIH meeting led to recommendations for conducting better clinical trials. PLoS Med 3 2006; 6: E144.
15. Kauchali S, Rollins N, Van den Broeck J, on behalf of the Child Health Group. Local beliefs about childhood diarrhoea: importance for healthcare and research. J Trop Pediatr 2004; 50: 82-9.
16. Editorial. Safety concerns at the FDA. Lancet 2005; 365: 727-8.
17. Ioannidis JP, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet 1998; 352: 1752-3.